Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Detection and Prevalence of Penicillin-Susceptible Staphylococcus aureus in the United States in 2013.

Richter SS, Doern GV, Heilmann KP, Miner S, Tendolkar S, Riahi F, Diekema DJ.

J Clin Microbiol. 2016 Mar;54(3):812-4. doi: 10.1128/JCM.03109-15. Epub 2016 Jan 13.

2.

Candidemia surveillance in Iowa: emergence of echinocandin resistance.

Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, Diekema D.

Diagn Microbiol Infect Dis. 2014 Jun;79(2):205-8. doi: 10.1016/j.diagmicrobio.2014.02.016. Epub 2014 Mar 1.

PMID:
24666704
3.

Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study.

Diekema DJ, Richter SS, Heilmann KP, Dohrn CL, Riahi F, Tendolkar S, McDanel JS, Doern GV.

Infect Control Hosp Epidemiol. 2014 Mar;35(3):285-92. doi: 10.1086/675283. Epub 2014 Jan 29.

PMID:
24521595
4.

Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Apr;49(4):1274-9. doi: 10.1128/JCM.02437-10. Epub 2011 Feb 2.

5.
6.
7.

Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2011 Feb;49(2):630-7. doi: 10.1128/JCM.02161-10. Epub 2010 Dec 15.

8.

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.

J Clin Microbiol. 2011 Feb;49(2):624-9. doi: 10.1128/JCM.02120-10. Epub 2010 Dec 8.

9.

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.

J Clin Microbiol. 2011 Feb;49(2):586-90. doi: 10.1128/JCM.02136-10. Epub 2010 Dec 1.

10.

Methicillin-resistant Staphylococcus aureus in pork production shower facilities.

Leedom Larson KR, Harper AL, Hanson BM, Male MJ, Wardyn SE, Dressler AE, Wagstrom EA, Tendolkar S, Diekema DJ, Donham KJ, Smith TC.

Appl Environ Microbiol. 2011 Jan;77(2):696-8. doi: 10.1128/AEM.01128-10. Epub 2010 Nov 19.

11.

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

Diagn Microbiol Infect Dis. 2010 May;67(1):56-60. doi: 10.1016/j.diagmicrobio.2010.01.001. Epub 2010 Mar 5.

PMID:
20207095
12.

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ.

J Clin Microbiol. 2010 Jan;48(1):52-6. doi: 10.1128/JCM.01590-09. Epub 2009 Nov 18.

13.

In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S, Pfaller MA.

J Clin Microbiol. 2009 Oct;47(10):3170-7. doi: 10.1128/JCM.00942-09. Epub 2009 Aug 26.

14.

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.

15.

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ; ARTEMIS DISK Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2009 Sep;65(1):27-34. doi: 10.1016/j.diagmicrobio.2009.05.007.

PMID:
19679232
16.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.

Pfaller MA, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3185-90. doi: 10.1128/JCM.00946-09. Epub 2009 Aug 5.

17.

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.

Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN, Pfaller MA.

Diagn Microbiol Infect Dis. 2009 Feb;63(2):233-6. doi: 10.1016/j.diagmicrobio.2008.11.001. Epub 2008 Dec 12.

PMID:
19070452
18.

Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.

Pfaller MA, Boyken LB, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2008 Nov;46(11):3585-90. doi: 10.1128/JCM.01391-08. Epub 2008 Sep 10.

19.

In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2008 Aug;46(8):2568-72. doi: 10.1128/JCM.00535-08. Epub 2008 Jun 18.

20.

Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection.

Huang SS, Diekema DJ, Warren DK, Zuccotti G, Winokur PL, Tendolkar S, Boyken L, Datta R, Jones RM, Ward MA, Aubrey T, Onderdonk AB, Garcia C, Platt R.

Clin Infect Dis. 2008 Apr 15;46(8):1241-7. doi: 10.1086/529381.

21.
22.

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2008 Jan;46(1):150-6. Epub 2007 Nov 21. Erratum in: J Clin Microbiol. 2008 Sep;46(9):3184-5.

23.

Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Diekema DJ, Messer SA, Hollis RJ, Boyken LB, Tendolkar S, Kroeger J, Pfaller MA.

J Clin Microbiol. 2007 Jun;45(6):1974-7. Epub 2007 Feb 14.

24.

Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.

Messer SA, Diekema DJ, Hollis RJ, Boyken LB, Tendolkar S, Kroeger J, Pfaller MA.

J Clin Microbiol. 2007 Apr;45(4):1322-4. Epub 2007 Jan 31.

26.

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2006 Oct;44(10):3533-8.

27.

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2006 Mar;44(3):760-3.

28.

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA.

J Clin Microbiol. 2006 Feb;44(2):324-6.

29.

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2005 Nov;43(11):5425-7.

30.

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP.

Antimicrob Agents Chemother. 2005 Nov;49(11):4795-7.

31.
33.

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ.

J Clin Microbiol. 2005 May;43(5):2163-7.

34.
35.
36.
40.
41.

Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2004 Jan;42(1):380-3.

42.

Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 Dec;41(12):5729-31.

43.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 May;41(5):2176-9.

44.
45.

Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood.

Maxwell MJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Diekema DJ, Pfaller MA.

J Clin Microbiol. 2003 Mar;41(3):1087-90.

Supplemental Content

Loading ...
Support Center